Argenx stock holds strong as key biotech holding with robust market value

Published on 09/14/2026 at 15:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock remains a core position in RTW Biotech Opportunities with a 6.1 percent NAV weight as of August 2026. The company’s market capitalization stands above EUR 52 billion as of September 12, 2026, underlining its role as a heavyweight in European biotech.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) continues to trade as a heavyweight biotech name, underlined by a market capitalization of about EUR 52.76 billion reported for September 12, 2026 and its prominent role in specialized healthcare portfolios.

Argenx remains a top holding in biotech portfolio

Argenx SE is increasingly positioned as a core biotech exposure in institutional portfolios. According to Investing.com on September 14, 2026, Argenx (ticker ARGX) accounted for 6.1 percent of net asset value in the RTW Biotech Opportunities fund’s August 2026 factsheet, second only to CG Oncology at 7.5 percent.

That weight confirms Argenx as one of the largest single positions in the fund and reflects strong conviction in its antibody-based pipeline. The same update shows Argenx alongside other high-conviction names, signaling that the company’s fundamentals and clinical outlook remain attractive enough to justify a mid-single-digit NAV allocation in a diversified biotech portfolio.

Market capitalization and return metrics underline scale

The scale of Argenx in public markets is equally visible in current valuation metrics. As of September 12, 2026, Argenx’s market capitalization was reported at EUR 52.76 billion, with a level of EUR 52.66 billion cited by Nasdaq data and EUR 52.76 billion by CompaniesMarketCap, placing the stock around the 412th most valuable company globally by market cap in 2026.

This valuation compares with an earlier market cap of EUR 52.66 billion on the same date, implying a modest increase of EUR 0.10 billion that fits into a broader 2026 market cap change of about 17.81 percent for the year according to the CompaniesMarketCap overview. The double-digit year-to-date increase suggests that Argenx has benefited from strong investor demand relative to late 2025 levels, even as individual trading days show only small percentage moves.

Profitability metrics complement the market cap picture. A 2026 ranking of healthcare stocks by return on assets lists Argenx with a return on assets of 14.88 percent and a market capitalization of USD 61.58 billion, compared with Vertex Pharmaceuticals at 15.42 percent ROA and USD 130.64 billion market cap, highlighting Argenx’s efficient asset use in relation to peers in the sector.

Long-term performance and analyst interest

For long-term investors, Argenx’s performance over the past decade has been notable. A ten-year investment example shows that a hypothetical stake worth EUR 10,000 in 2016 would have grown to EUR 563,564.36 by September 11, 2026, based on a last recorded price of EUR 853.80 per share, translating into a cumulative gain of 5,535.64 percent over that period according to a retrospective performance analysis on a German financial portal.

On the same date, the portal reported a recent price around EUR 862.80 with a daily gain of 1.13 percent and a market capitalization near EUR 53.41 billion, underscoring that Argenx’s strong multi-year performance has been accompanied by continued interest from both retail and institutional investors.

Analyst coverage mirrors that interest. The performance overview lists several recent ratings: Barclays Capital maintained an Overweight rating on Argenx on August 8, 2026, while Jefferies & Company Inc. reiterated a Buy rating on September 3, 2026 and UBS AG also carried a Buy stance as of August 26, 2026. These ratings indicate that multiple houses still see upside in Argenx shares, even after the significant appreciation of the past decade, though individual price targets are not detailed in the same snapshot.

Trading profile and European listing context

Argenx is listed in Europe under ISIN NL0010832176, with recent trading data from a Dutch investor forum indicating a last price of EUR 607.00, a slight decline of 0.07 percent, and trading volume of 4,163 shares against a three-month average volume of 95,100 shares. The narrow bid-ask spread between EUR 606.80 and EUR 607.20 points to orderly trading conditions at this venue.

While the European quote reflects local investor activity, investors globally tend to focus on Argenx’s valuation in both euros and dollars. The combination of a market cap above EUR 52 billion and a return on assets near 15 percent positions the company as a large-cap growth and profitability story in the biotech space, comparable in efficiency metrics to some much larger US peers.

Stock level and investor takeaway

As of September 12, 2026, the reference market capitalization of Argenx stands at EUR 52.76 billion, and recent European trading shows the stock around the EUR 600 to EUR 860 band depending on venue and day. For investors, the key takeaway is that Argenx stock couples large-cap scale with strong long-term returns and remains a meaningful holding in specialized biotech funds, supported by recent Overweight and Buy ratings from houses such as Barclays, Jefferies and UBS.